Banque Pictet & Cie SA lessened its position in DexCom, Inc. (NASDAQ:DXCM) by 22.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,900 shares of the medical device company’s stock after selling 8,700 shares during the period. Banque Pictet & Cie SA’s holdings in DexCom were worth $2,188,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in DXCM. BlackRock Inc. increased its holdings in shares of DexCom by 5,000.4% in the 1st quarter. BlackRock Inc. now owns 4,160,862 shares of the medical device company’s stock worth $352,550,000 after acquiring an additional 4,079,283 shares during the period. FMR LLC increased its holdings in shares of DexCom by 9.1% in the 1st quarter. FMR LLC now owns 9,845,408 shares of the medical device company’s stock worth $834,201,000 after acquiring an additional 823,406 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of DexCom by 27.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,242,928 shares of the medical device company’s stock worth $237,221,000 after acquiring an additional 696,199 shares during the period. Janus Capital Management LLC increased its holdings in shares of DexCom by 12.2% in the 1st quarter. Janus Capital Management LLC now owns 4,001,971 shares of the medical device company’s stock worth $339,083,000 after acquiring an additional 436,162 shares during the period. Finally, Morgan Stanley increased its holdings in shares of DexCom by 18.0% in the 1st quarter. Morgan Stanley now owns 2,092,962 shares of the medical device company’s stock worth $177,336,000 after acquiring an additional 319,631 shares during the period.

TRADEMARK VIOLATION WARNING: “Banque Pictet & Cie SA Has $2.19 Million Position in DexCom, Inc. (DXCM)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/04/banque-pictet-cie-sa-has-2-19-million-position-in-dexcom-inc-dxcm.html.

A number of research firms recently weighed in on DXCM. Jefferies Group LLC dropped their price objective on shares of DexCom to $91.00 and set a “buy” rating on the stock in a report on Tuesday, May 9th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $90.00 price objective (down previously from $105.00) on shares of DexCom in a report on Tuesday, August 8th. Canaccord Genuity reaffirmed a “buy” rating and issued a $90.00 price objective on shares of DexCom in a report on Wednesday, June 7th. Zacks Investment Research upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Finally, ValuEngine upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research report on Friday. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $87.00.

DexCom, Inc. (DXCM) opened at 74.96 on Monday. The company’s market cap is $6.49 billion. The stock’s 50 day moving average is $71.54 and its 200 day moving average is $74.57. DexCom, Inc. has a 52-week low of $57.68 and a 52-week high of $96.38.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. The firm had revenue of $170.60 million during the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.24) EPS. Equities research analysts forecast that DexCom, Inc. will post ($0.77) earnings per share for the current year.

In other DexCom news, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $69.07, for a total transaction of $414,420.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Steven Robert Pacelli sold 1,450 shares of the business’s stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $78.19, for a total value of $113,375.50. The disclosure for this sale can be found here. Insiders have sold a total of 32,179 shares of company stock valued at $2,282,217 over the last three months. Company insiders own 1.70% of the company’s stock.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.